Welcome to the KCAMA & Dr. Nizar Tannir Rare Scholar Program Submission Portal
The KCA is committed to nurturing the next generation of leaders in kidney cancer research and treatment through two distinct mentorship programs. The one-year Mentorship Academy focuses on clinicians in the U.S., while the two-year Dr. Nizar Tannir Rare Kidney Cancer Scholar Program offers a specialized curriculum for those interested in rare kidney cancers and is open to participants worldwide. These programs provide invaluable guidance, training, and networking opportunities to advance careers and enhance the field of kidney cancer care.
Apply now to be part of these transformative experiences and contribute to the future of kidney cancer research.
KCAMA Program Co-Chairs
Mentors:
- Eric A. Singer, MD, MA, MS, FACS, FASCO – OSU
- Brian I. Rini, MD, FASCO – Vanderbilt
- Sumanta K. Pal, MD, FASCO – City of Hope
- Dan J. George, MD – Duke University
- Brad C. Leibovich, MD, FACS – Mayo Clinic
- Walt M. Stadler, MD – University of Chicago
- Pavlos Msaouel, MD, PhD – MD Anderson
- Jose A. Karam, MD, FACS – MD Anderson
SUBMIT YOUR APPLICATION TODAY!
REMAINING TO SUBMIT AN APPLICATION
Deadline is September 30, 2024, 11.59PM
IMPORTANT UPDATE: We are currently not accepting new submissions, the portal will remain open until Oct 7, 2024 at 23.59, only for applicants that have submitted incomplete applications to let them finish their submission.
For any questions, please send an email to grants@kidneycancer.org
- Brian M. Shuch, MD – UCLA
- Ron M. Bukowski, MD – Cleveland Clinic
- Tian Zhang, MD – UT Southwestern
- Eric A. Jonasch, MD – MD Anderson
- Chad Tang, MD – MD Anderson
- Raquibul Hannan, MD, PhD - UT Southwestern
- Nizar M. Tannir, MD, FACP - MD Anderson
- More to be confirmed
Compare the two programs here:
|
More detailed information: |
|
Introduction |
Dedicated to nurturing future leaders in kidney cancer research and treatment by providing mentorship and networking opportunities. Focuses on patient-facing early-career clinicians. |
|
Aims |
Shape the next generation of kidney cancer clinicians, trialists, and leaders. Provide engaging educational and interactive experiences focused on kidney cancer and clinical trial concepts. |
|
Eligibility |
Senior Fellows transitioning to faculty roles, Clinical Instructors, or up to Assistant Professors. Must possess a doctoral degree and have completed relevant clinical training. Employed or affiliated with an academic institution. Available to US Applicants only. (European Mentorship Academy to launch in 2026.) |
|
Application Requirements |
Cover Letter, Letter of Support from Division Chief/Program Director/Chair, Optional Letter of Support from Internal Mentor, Clinical Trial Protocol Idea, Forward-Looking Statements, Institutional Program supporting kidney cancer or GU cancer clinical trials. |
|
Selection Process and Mentor Pairing |
Applications reviewed based on eligibility and application components. Recipients selected based on commitment, qualifications, and potential for growth. Mentor assignment based on candidate preference and program committee discretion. |
|
Program Benefits |
Personalized mentorship, training, networking opportunities, speaking opportunities at IKCS meetings, and workshops. |
|
Program Timeline* |
Sept 30, 2024: Application deadline. |
|
How to Apply |
Submit the application, including all required documents, by the deadline. Applications are reviewed and scholars will be notified 10/15. |
* Every mentee's program will be tailor-made and might include different activities
|
Honors Dr. Nizar Tannir's legacy in kidney cancer research, mentorship, and advocacy. Focuses on rare kidney cancers like RMC, pRCC, chRCC, HLRCC, etc., aiming to cultivate leaders in rare kidney cancer treatment. |
|
|
Open to trainees/fellows or junior faculty within three years of completing their fellowship. Must possess a doctoral degree with relevant clinical or laboratory training. Affiliated with an academic or research institution supporting kidney cancer research. Applicants from both the United States and Europe are eligible. |
|
Cover Letter, Letters of Support from Division Chief/Program Director/Chair and Optional Internal Mentor, Personal Statement, Future Vision Statement, Institutional Program supporting kidney cancer or GU cancer clinical trials. |
|
Applications will be reviewed by a dedicated panel of rare kidney cancer experts. Recipients selected based on commitment, qualifications, and potential for growth. For its inaugural year, candidate will be paired with Dr Nizar Tannir and/or Dr. Pavlos Msaouel, both experts in rare RCCs. |
|
Personalized mentorship, training, networking, speaking opportunities, participation in patient advocacy events, symposiums, and direct engagement with KCA Affiliate Partners. |
|
Sept 30, 2024: Application deadline. |
|
Submit the application, including all required documents, by the deadline. Applications are reviewed and scholar will be notified 10/15. |